BMJ 2005;330 (29 January), doi:10.1136/bmj.330.7485.0
CMF adjuvant chemotherapy for breast cancer achieves good long term results
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer benefits the long term prognosis. After median follow up of 28.5 years, Bonadonna and colleagues (p 217) report combined results of two previously published randomised controlled trials and one observational study. Their experience shows that CMF adjuvant chemotherapy at least halves patients' long term risk of relapse and death.
|
|
Credit: SPL
|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Articles
- The GMC: expediency before principle: BMA chairman responds
- James Johnson
BMJ 2005 330: 252.[Extract] [Full Text] [PDF]
- "Disaster mental health": lessons from Aberfan
- Derek A Summerfield
BMJ 2005 330: 254.[Extract] [Full Text]
- 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
- Gianni Bonadonna, Angela Moliterni, Milvia Zambetti, Maria Grazia Daidone, Silvana Pilotti, Luca Gianni, and Pinuccia Valagussa
BMJ 2005 330: 217.[Abstract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article.Most read
Print issues
